Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytokinetics and other ETFs, options, and stocks.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
498
Employees498
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
498
Employees498

CYTK Key Statistics

Market cap
6.02B
Market cap6.02B
Price-Earnings ratio
-9.76
Price-Earnings ratio-9.76
Dividend yield
Dividend yield
Average volume
3.21M
Average volume3.21M
High today
$51.69
High today$51.69
Low today
$48.93
Low today$48.93
Open price
$50.30
Open price$50.30
Volume
1.94M
Volume1.94M
52 Week high
$59.39
52 Week high$59.39
52 Week low
$29.31
52 Week low$29.31

CYTK News

TipRanks 8h
Cytokinetics price target raised to $52 from $45 at BofA

BofA raised the firm’s price target on Cytokinetics (CYTK) to $52 from $45 and keeps a Neutral rating on the shares. The ESC conference “was a win for the compa...

Simply Wall St 1d
Cytokinetics Is Up 29.9% After Positive Aficamten Phase 3 Data and Regulatory Progress

In late August 2025, Cytokinetics presented new clinical data for aficamten at the European Society of Cardiology Congress in Madrid, with findings published in...

Cytokinetics Is Up 29.9% After Positive Aficamten Phase 3 Data and Regulatory Progress
TipRanks 1d
Cytokinetics Highlights Aficamten Data at ESC Congress

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

Analyst ratings

82%

of 22 ratings
Buy
81.8%
Hold
18.2%
Sell
0%

More CYTK News

TipRanks 2d
Top Executives Cash In on Cytokinetics Stock Sales!

New insider activity at Cytokinetics ( (CYTK) ) has taken place on September 2, 2025. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50%...

TipRanks 2d
H.C. Wainwright sees ‘little room left for doubt’ on Cytokinetics’ aficamten

H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating and $120 price target on Cytokinetics (CYTK) after the company hosted an investor event to disc...

Benzinga 2d
Cytokinetics Stock Is Skyrocketing Tuesday: What's Driving The Action?

Shares of Cytokinetics, Inc. CYTK are trading sharply higher Tuesday after the biopharmaceutical company presented new data highlighting the long-term safety an...

Cytokinetics Stock Is Skyrocketing Tuesday: What's Driving The Action?
TipRanks 2d
Cytokinetics Receives Buy Rating from James Condulis Amid Promising Developments and Strategic Partnerships

James Condulis, an analyst from Stifel Nicolaus, maintained the Buy rating on Cytokinetics. The associated price target was raised to $96.00. Elevate Your Inves...

TipRanks 3d
Cytokinetics presents additional data from MAPLE-HCM study

Cytokinetics (CYTK) announced that additional data related to aficamten were presented at the European Society of Cardiology Congress 2025 in Madrid, Spain, inc...

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.